medicamentos glp 1 🚨 LA NUEVA COMPETENCIA EN OBESIDAD ES ORAL: ORFORGLIPRON VS. WEGOVY®️ PILL Dos agonistas del receptor GLP-1 administrados una vez al día, pero con diferencias importantes. Orforglipron es una molécula pequeña no Weight-Loss Medications Are Effective for

Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1RA) in high-risk patients with type 2 diabetes

The FDA emphasized that compounded drugs are not FDA approved and therefore are not reviewed by the agency for safety, effectiveness, or quality before marketing

This article has been updated by The Pharmaceutical Journal team and reviewed by the expert authors to ensure it remains relevant and up to date, following its original publication in December 2025

They are used in T2DM, obesity, and increasingly in cardiovascular risk reduction

If approved, orforglipron would be the first oral GLP-1 receptor agonist approved for weight loss